Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Healthcare worker measuring tension on a patient © Credit Rama George Alleyne, World Bank
Load More

Similar stories

Real-time genetic surveillance can support timely, evidence-based responses to shifting malaria threats

A sharp decline in piperaquine-resistant strains of P. Falciparum malaria following drug policy revisions across the Greater Mekong Subregion (GMS) highlights how real-time genetic data can support timely, evidence-based responses to shifting malaria threats, say researchers in a study published in Nature Communications.